Biocon Biologics is a global biopharmaceutical company focused on making biosimilar therapies more accessible worldwide. It positions itself as a fully integrated biosimilars leader and part of the Biocon group.
Biocon's Yesafili, an interchangeable aflibercept biosimilar, is now available in the U.S., while Zydus Lifesciences launched Anyra in India. Both aim to treat retinal diseases such as diabetic macular edema. Biocon plans further launches in the UK and other markets, as competition intensifies.
Multiple market reports forecast the global biologics and antibody therapy markets will reach hundreds of billions of dollars by the 2030s, driven by monoclonal antibodies, biosimilar expansion, and targeted therapies.
U.S. insulin glargine and biosimilar developments in 2026 included CivicaScript's low-cost launch and California's CalRx rollout. The global insulin biosimilars market reached US$2.5 billion in 2025 and is projected to reach US$6.0 billion by 2033.
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06016387 |
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study |
RECRUITING | PHASE2 |
